Home
SAiGENCI is an independent cancer-focused medical research institute located in South Australia; focusing on cancer research and linking to clinical trials, which include new cutting-edge technologies in immunotherapies and genomics.
Help make cancer history
100% of your gift will support leading-edge cancer research, which will lead to better outcomes for patients with cancer, and their families.
With your support, we can save lives.
Sign up to our mailing list
Keep up to date with how we are changing the future of cancer treatment.
Featured projects
Winning the ‘chess’ game against cancer
How a powerful computer modelling approach could predict cancer’s “next move” when faced with targeted treatments.
Read more about Winning the ‘chess’ game against cancer
Developing the first drug for multi-organ radiation protection
A pharmaceutical breakthrough at the University of Adelaide is showing promise in both multi-organ radiation protection and cancer treatment.
Read more about Developing the first drug for multi-organ radiation protectionLeadership appointments
Professor Christopher Sweeney
Professor Christopher Sweeney is SAiGENCI's inaugural Director.
Professor Lisa Butler
Professor Lisa Butler is Program Lead for the Resistance Prevention program. She also leads SAiGENCI’s Graduate Program for HDR and Honours students.
Professor Brendan Jenkins
Professor Brendan Jenkins is Program Lead for the Tumour Inflammation and Immunotherapy program.
Professor Lan Nguyen
Professor Lan Nguyen is Program Lead for the Computational Systems Oncology program.
Professor Jose Polo
Professor Jose Polo is Program Lead for Cancer Epigenetics in SAiGENCI, building the epigenetics capacity within the Institute. Professor Polo has established the Adelaide Centre for Epigenetics (ACE).
News
10 Dec
Breakthroughs in ubiquitin biology highlighted at inaugural Australian Ubiquitin Summit
The inaugural Lorne Ubiquitin Australian Ubiquitin Summit 2025, held from 16-20 of November in Lorne, Victoria, brought together leading scientists, clinicians, and industry innovators to explore one of the most dynamic areas of modern biomedical research: ubiquitin biology and targeted protein degradation (TPD). 01 Dec
SAiGENCI welcomes 2025/26 Summer Research cohort
SAiGENCI kicked off it’s 2025/26 summer research program with a morning tea last week, celebrating the arrival of this year’s students.
